ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO0687

Clinical Characteristics and Short-Term Outcomes of Severe AKI in COVID-19 in Bronx, New York

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)


  • Yunes, Milagros, Montefiore Medical Center, Bronx, New York, United States
  • Alahiri, Emad, Montefiore Medical Center, Bronx, New York, United States
  • Mocerino, Ryan, Montefiore Medical Center, Bronx, New York, United States
  • Prudhvi, Kalyan, Montefiore Medical Center, Bronx, New York, United States
  • Golestaneh, Ladan, Montefiore Medical Center, Bronx, New York, United States
  • Fisher, Molly, Montefiore Medical Center, Bronx, New York, United States

After the first reported case of COVID-19 in the U.S., New York City quickly became the epicenter of the pandemic. AKI has been reported in patients with severe COVID-19. The Bronx consists of a predominantly minority population with a high burden of comorbidities that may be at increased risk for AKI in the setting of COVID-19. We aimed to characterize risk factors and short term outcomes in patients hospitalized with COVID-19 and severe AKI.


We performed a retrospective study of 113 adults hospitalized with COVID-19 in a large healthcare system in the Bronx who required nephrology consultation for AKI from March 11-March 30, 2020. We extracted data on demographics, comorbidities, admission vital signs and labs, need for mechanical ventilation, renal replacement therapy (RRT), in-hospital death and discharge. AKI was defined by KDIGO criteria. Chi-square analyses and Wilcoxon tests were used. Data was censored on April 12, 2020. All patients had > 14 days of follow up.


Mean age was 63 (SD 12) years old; 69% were men and 33% were Black and 23% were Hispanic. Forty-five patients (39.8%) had chronic kidney disease, 58(51%) had diabetes mellitus and 87(77%) had hypertension. The majority presented with AKI within 24 hours of admission and 75% had Stage 3 AKI. Ninety-two (81%) patients had proteinuria and 53(47%) had hematuria. Intensive care unit (ICU) was required in 62(55%), 64(57%) required mechanical ventilation, 56(49.5%) required RRT and 18(16%) were not candidates for RRT. In-hospital death occurred in 68(60%) and 22% were discharged. Of those who required RRT, in-hospital death occurred in 35(62.5%) and only 6 patients were discharged, 5 of whom remained RRT dependent. Heavy proteinuria (3-4+ on urinalysis) and initial C-reactive protein (CRP) were higher in those with AKI who died [21.1 (IQR 14.3-29.6) versus 6.6 (3.2-16.3), p<0.001].


Severe AKI in the setting of COVID-19 is associated with increased utilization of ICU, mechanical ventilation, and RRT. Outcomes are poor in those with Stage 3 AKI, underscoring the need for palliative care involvement and early goals of care discussions. Elevated initial CRP and heavy proteinuria may be useful to risk stratify patients with COVID-19 and severe AKI at increased risk for mortality.